News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Active Biotech AB Advances ANYARA into Phase III Clinical Trial
May 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN--(Marketwire - May 13, 2008) - Lund, Sweden, May 13, 2008 - An interim analysis has been performed in Active Biotech AB's (OMX Nordic: ACTI) ongoing Phase II/III clinical study of ANYARA, in patients with advanced renal cell cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
·
1 min read
·
Lori Ellis
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
·
2 min read
·
Tristan Manalac
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
·
3 min read
·
Heather McKenzie
